Deutsches Ärzteblatt international
Cure8 research brief
Why This Matters
Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which biologics have pediatric data and where evidence is lacking.
Who Should Pay Attention
Pediatric patients with refractory IBD, parents/caregivers, pediatric gastroenterologists, and researchers focused on pediatric IBD therapies
Study Snapshot
Story typeClinical Reference
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This narrative review summarizes current pediatric management of refractory IBD using guideline sources and selective literature searches. It emphasizes a standardized re-evaluation (clinical exam, biomarkers, endoscopy/imaging, and therapeutic‑drug‑monitoring) before switching drug classes.
After anti‑TNF failure, ustekinumab (approved for Crohn’s in patients ≥2 years) and vedolizumab (commonly used off‑label in pediatrics) are the best‑established options; reported pediatric remission rates cited in the review include ~51% at week 52 for ustekinumab and 32–42% at week 14 for vedolizumab depending on diagnosis.
Evidence for IL‑23p19 antibodies, JAK inhibitors, and S1P modulators in children is limited and mainly extrapolated from adult studies; the authors call for prospective pediatric trials, registry data, and structured algorithms. They recommend management in experienced interdisciplinary centers, with surgery remaining important for complicated disease.
Keep In Mind
This is a narrative review summarizing guidelines and selected studies (abstract-level content). Many newer drugs lack robust pediatric trial data and are used off‑label; prospective pediatric studies and registries are needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDeutsches Ärzteblatt international
AuthorsF A Rommel, Christa Bergheim, Ralph Melchior +3 more
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 22, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
Postoperative Complications Associated with Advanced Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...